MA-ABIOMED
20.9.2022 02:25:27 CEST | Business Wire | Press release
Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005279/en/
Caption: The investigator-led Inova, NCSI and J-PVAD studies all demonstrate an improvement from the historical AMI cardiogenic shock survival rate of approximately 50% when patients are treated with best practices including Impella. (Graphic: Business Wire)
The analysis examined 293 consecutive Impella-supported AMICS patients in the J-PVAD Registry, a registry conducted by 10 Japanese professional societies, including the Japanese Circulation Society (JCS). Results demonstrated 81% survival at 30 days. Historical cardiogenic shock survival rates without Impella are approximately 50%.
“The results of this study demonstrate that when Impella is used and best practices are followed, it is possible to achieve heart recovery and greater than 80% survival rates for patients with AMI cardiogenic shock,” said lead investigator Junya Ako, MD, an interventional cardiologist and chair of the department of cardiovascular medicine at Kitasato University Hospital in Kanagawa.
These results are consistent with other published investigator-led studies, such as the National Cardiogenic Shock Initiative Study (NCSI) and the Inova study by Tehrani et al., that have demonstrated significant increases in survival with the use of Impella and best practices such as placing Impella prior to percutaneous coronary intervention (PCI) (see figure 1).
J-PVAD data is independently monitored and shared with the Japan Pharmaceuticals and Medical Devices Agency (PMDA).
ABOUT IMPELLA HEART PUMPS
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (ABMD), is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training10.9.2026 12:35:00 CEST | Press release
Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants Training guidance is designed to prepare healthcare providers to deliver high-quality treatment experiences to patients receiving COMP360, if approved Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved. The recipients were selected through a competitive application process based on their expertise and proven abilit
Compass Pathways to Participate in Investor Conferences the Week of September 14th10.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on September 15, 2026 Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY: Fireside chat at 11:30am ET on September 16, 2026 Deutsche Bank’s 2026 Healthcare Summit – New York, NY: Fireside chat at 11:00am ET on September 17, 2026 A live audio webcast of the fireside chats will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlockin
GasEntec Announces New Ownership Structure, Accelerating Next Phase of Global Growth10.9.2026 11:00:00 CEST | Press release
Independent LNG infrastructure and technology company expands investment in proprietary technology, modular solutions and global project development. GasEntec Holdings Inc., a global LNG technology and assets company, today announced a new ownership structure designed to accelerate GasEntec’s next phase of growth and expand the commercialization of its proprietary LNG technologies and solutions. A consortium led by the Groupe Mimran has acquired a majority stake in GasEntec Holdings Inc., the US holding company, supporting GasEntec’s global growth. Under the new structure, GasEntec Holdings is the parent company of GasEntec’s South Korean operating business. Prior shareholders have exited in full. GasEntec’s customer relationships, contracts, engineering organization and ongoing global operations remain unchanged. GasEntec will continue to operate independently, with its technology development, engineering and operations centered in South Korea and an expanding commercial presence acro
EUMETSAT Takes Control of MTG-I210.9.2026 09:30:00 CEST | Press release
EUMETSAT’s Mission Control Centre in Darmstadt, Germany, took over control of the newest addition to its fleet of meteorological satellites, Meteosat Third Generation Imager 2 (MTG-I2), on 9 September 2026, following the successful completion of its Launch and Early Orbit Phase (LEOP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909889951/en/ MTG-I2 in orbit MTG-I2 launched from Europe’s Spaceport in French Guiana on 27 August 2026 and has now reached its geostationary orbit, around 36,000 km above Earth. During LEOP, carried out for EUMETSAT by Telespazio, communications with the satellite were established, its solar arrays deployed and a series of precise manoeuvres brought it to its designated orbital position. The spacecraft has now been handed over to EUMETSAT’s flight operations teams. EUMETSAT, working with ESA and European industry, will now begin extensive calibration and validation activities to prepare the s
LUMI AI Factory Selects IQM's Staged Path to Europe's First Superconducting Quantum Computer With Logical Qubits10.9.2026 09:08:00 CEST | Press release
The upgrade path contains three stages from IQM´s Halocene product line to enable a logical qubit system. The quantum computer, as part of the LUMI AI Factory initiative, is jointly owned by the participating countries of Finland, Czechia, Norway and Poland, and jointly funded by the EuroHPC Joint Undertaking. The system will be installed at CSC – IT Center for Science in Finland and integrated into the LUMI-AI computing environment to form a hybrid HPC, AI, and quantum computing platform. The deployments are in line with IQM’s development roadmap for fault-tolerant quantum computing by 2030. IQM Quantum Computers (Nasdaq: IQMX) today announced its upgrade path for a logical-qubit-capable quantum computer. The deployment to the LUMI AI Factory, led by CSC – IT Center for Science, will support R&D efforts toward fault-tolerant quantum computing and advancements in hybrid computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom